The management of plasma cell neoplasms.
D000682:Amyloid / Q000096:biosynthesis; D000686:Amyloidosis / Q000150:complications; D000740:Anemia / Q000209:etiology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000150:complications; D006801:Humans; D005779:Immunodiffusion; D007122:Immunoelectrophoresis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007136:Immunoglobulins / Q000032:analysis; D007239:Infections / Q000209:etiology; D007945:Leukemia, Lymphoid / Q000150:complications; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications; D008228:Lymphoma, Non-Hodgkin / Q000150:complications; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000401:mortality; D011379:Prognosis; D011704:Pyelonephritis / Q000209:etiology
D000682:Amyloid; D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D003520:Cyclophosphamide; D008558:Melphalan